Sona Nanotech's THT Shows Potential in Preventing Tumor Formation and Recurrence
Sona Nanotech (CSE:SONA,OTCQB:SNANF) announced results from biomarker analysis of a recent pre-clinical melanoma study, reporting that its Targeted Hyperthermia Therapy (THT) can not only shrink existing tumors, but under specific circumstances can also trigger an immune system to prevent new tumors from forming. The pre-clinical study, which was conducted at Dalhousie University, revealed that Sona's THT stimulates the immune system to target and eliminate distant tumors when combined with the immunotherapeutic drug IL-2. In a Wednesday (June 26) press release, Dr. Carman Giacomantonio, Sona'...